NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00050999,Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients,https://clinicaltrials.gov/study/NCT00050999,,COMPLETED,The purpose of this study is to compare the effectiveness of two dose levels of ONTAK (denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell lymphoma.,NO,"Lymphoma, T-Cell, Cutaneous|Mycosis Fungoides|Sezary Syndrome",DRUG: ONTAK,"Objective Rate of Response (ORR), defined as CR + CCR + PR",Time-to-Treatment Failure|Time-to-Progression|Duration of Response,,Eisai Inc.,,ALL,"ADULT, OLDER_ADULT",PHASE4,195,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT,93-04-11,1995-06,2006-09,2006-12,2003-01-03,,2008-03-05,"University of Texas, M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|Level 4 Department of Haematology Royal North Shore Hospital, St. Leonard's, New South Wales, 2065, Australia|Westmead Hospital, Department of Haematology, Westmead, New South Wales, 2145, Australia|Mater Misericordiae Adult Hospital, South Brisbane, Queensland, 4101, Australia|Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital, Woolloongabba, Queensland, 4102, Australia|LKH Universitatsklinikum Graz, Graz, A-8036, Austria|Allgemeines Krankenhaus der Stadt Wien, Vienna, A-1090, Austria|Cross Cancer Centre, Edmonton, Alberta, Canada|Hamilton Regional Cancer Center, Hamilton, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Universitatsklinikum Charite, Berlin, Germany|University of Erlangen, Erlangen, 91052, Germany|Universitatsklinikum Essen, Essen, 45122, Germany|J.W. Goethe University Frankfurt, Frankfurt, 60590, Germany|Universitatskrankenhaus Eppendorf, Hamburg, 20246, Germany|Universitatsklinikum Mannheim, Mannheim, 68135, Germany|Universitatsklinikum Munster, Munster, D-48149, Germany|Sektion Dermatologische Onkologie, Tubingen, D-72076, Germany|LUMC, Department of Dermatology, Leiden, 2333 ZA, Netherlands|Medical Academy in Gdansk, Dept. of Hematology, Gdansk, 80-952, Poland|Regional Oncological Center, Dept. of Chemotherapy, Lodz, 93-509, Poland|Klinika Hematoonkologii Akademii Medycznej w Lublinie, Lublin, 20-950, Poland|Oddzial Chorob Wewnetrznych i Hematologii, Poznan, 61-833, Poland|The Medical University of Warsaw, Central Clinical Hospital, Warsaw, 02-097, Poland|Centrum Onkologii-Instytut im. Marii Sklodoskiej-Curie, Warsaw, 02-781, Poland|Blokhin Russian Cancer Research Center, RAMS, Moscow, Russian Federation|Burdenko Main Military Clinical Hospital, Moscow, Russian Federation|Central Research Institute of Skin and Venereal Diseases, Moscow, Russian Federation|Haematology Research Center RAMS, Moscow, Russian Federation|Samara Regional Clinical Hospital, Samara, 443095, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|Universitatsspital Zurich Dermatologische Klinik, Zurich, Switzerland|St. John's Institute of Dermatology, London, United Kingdom|City Hospital, Nottingham, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",
